[go: up one dir, main page]

AU1168099A - Formulations comprising dissolved paroxetine - Google Patents

Formulations comprising dissolved paroxetine Download PDF

Info

Publication number
AU1168099A
AU1168099A AU11680/99A AU1168099A AU1168099A AU 1168099 A AU1168099 A AU 1168099A AU 11680/99 A AU11680/99 A AU 11680/99A AU 1168099 A AU1168099 A AU 1168099A AU 1168099 A AU1168099 A AU 1168099A
Authority
AU
Australia
Prior art keywords
paroxetine
solid
carrier
capsule
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11680/99A
Other languages
English (en)
Inventor
Ahmad Ghazawi
Graham Stanley Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU1168099A publication Critical patent/AU1168099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU11680/99A 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine Abandoned AU1168099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation
GB9724544 1997-11-21
PCT/GB1998/003471 WO1999026625A1 (fr) 1997-11-21 1998-11-18 Formulations contenant de la paroxetine dissoute

Publications (1)

Publication Number Publication Date
AU1168099A true AU1168099A (en) 1999-06-15

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11680/99A Abandoned AU1168099A (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Country Status (24)

Country Link
EP (1) EP1033986A1 (fr)
JP (1) JP2001523718A (fr)
KR (1) KR20010032320A (fr)
CN (1) CN1279608A (fr)
AP (1) AP2000001821A0 (fr)
AR (1) AR015485A1 (fr)
AU (1) AU1168099A (fr)
BG (1) BG104527A (fr)
BR (1) BR9814220A (fr)
CO (1) CO4970832A1 (fr)
DZ (1) DZ2658A1 (fr)
EA (1) EA200000552A1 (fr)
GB (1) GB9724544D0 (fr)
HU (1) HUP0100580A3 (fr)
IL (1) IL136106A0 (fr)
MA (1) MA24704A1 (fr)
NO (1) NO20002590L (fr)
OA (1) OA11385A (fr)
PE (1) PE20000381A1 (fr)
PL (1) PL340555A1 (fr)
SK (1) SK7342000A3 (fr)
TR (1) TR200001423T2 (fr)
WO (1) WO1999026625A1 (fr)
ZA (1) ZA9810637B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
JP4854115B2 (ja) * 1999-03-12 2012-01-18 エイシカ ファーマシューティカルス リミテッド 無水パロキセチン用安定製剤形
WO2001002393A1 (fr) 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes de paroxetine, avec des cyclodextrines et des derives de la cyclodextrine
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
EP1455763B1 (fr) * 2001-12-21 2007-10-03 Supernus Pharmaceuticals, Inc. Formulation de gelule a administration orale presentant une stabilite physique accrue
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (fr) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S Composition pharmaceutique comprenant un antagoniste de l'aldosterone
JP2013512948A (ja) * 2009-12-08 2013-04-18 イル・ファ・カンパニー・リミテッド ２０−Ｏ−β−Ｄ−グルコピラノシル−２０（Ｓ）−プロトパナキサジオールを含む固体分散体
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (fr) * 1995-04-03 1996-10-10 Abbott Laboratories Melanges homogenes de medicaments fondant a basse temperature et d'additifs, destines a une liberation lente
CA2277480A1 (fr) * 1997-01-15 1998-07-23 Neal Ward Compositions a base de paroxetine

Also Published As

Publication number Publication date
BR9814220A (pt) 2001-12-26
EA200000552A1 (ru) 2000-10-30
IL136106A0 (en) 2001-05-20
HUP0100580A3 (en) 2002-05-28
KR20010032320A (ko) 2001-04-16
MA24704A1 (fr) 1999-07-01
BG104527A (en) 2001-04-30
ZA9810637B (en) 2000-05-22
PE20000381A1 (es) 2000-05-07
DZ2658A1 (fr) 2003-03-22
NO20002590L (no) 2000-07-19
GB9724544D0 (en) 1998-01-21
NO20002590D0 (no) 2000-05-19
AP2000001821A0 (en) 2000-06-30
HUP0100580A2 (hu) 2002-04-29
AR015485A1 (es) 2001-05-02
JP2001523718A (ja) 2001-11-27
TR200001423T2 (tr) 2000-10-23
WO1999026625A1 (fr) 1999-06-03
OA11385A (en) 2004-01-27
EP1033986A1 (fr) 2000-09-13
SK7342000A3 (en) 2000-12-11
CN1279608A (zh) 2001-01-10
CO4970832A1 (es) 2000-11-07
PL340555A1 (en) 2001-02-12

Similar Documents

Publication Publication Date Title
US6524615B2 (en) Controlled release pharmaceutical composition
CA2627351C (fr) Systeme matriciel double a liberation lente a base d'excipients lipophiles
AU2006311818B9 (en) Improved delivery of tetrahydrocannabinol
TWI490216B (zh) 用作ｃ型肝炎病毒蛋白酶抑制劑之醫藥組合物
DK170209B1 (da) Ranitidinholdigt kapselpræparat og ikke-vandigt flydende præparat
WO2002011701A1 (fr) Composition pharmaceutique a liberation controlee
AU2016203127B2 (en) An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
BRPI0715423A2 (pt) formulaÇÕes para Éteres de benzimidazolil piridila
AU1168099A (en) Formulations comprising dissolved paroxetine
CA2656540A1 (fr) Capsules dures emplies d'un liquide contenant de l'ibuprofene
AU2013213706B2 (en) An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
KR100679582B1 (ko) 경질 쉘 캡슐용 이부프로펜 용액
US20020032220A1 (en) Formulations comprising dissolved paroxetine
WO2021163023A1 (fr) Formulations stables de dronabinol
JP6572244B2 (ja) 味覚マスキング薬製剤
CA2310407A1 (fr) Formulations contenant de la paroxetine dissoute
US20040146537A1 (en) Oily wax matrix suspension formulation comprising pharmacologically active agents
MXPA00005030A (en) Formulations comprising dissolved paroxetine
CZ20001876A3 (cs) Prostředky obsahující rozpuštěný paroxetin
KR20010078703A (ko) 신규 제약 제제

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted